InvestSMART

Control Bionics Limited (ASX: CBL) - Share Price

Current share price for CBL : $0.074 0.001 (1.33%)+

Control Bionics Limited (CBL), an ASX-listed company, is a Company that is engaged in development, commercialisation and sale of assistive communications technology systems within the disability sector.

CBL General Information +

ASX Code CBL
Website N/A
Industry/Sector Health Care Equipment
Market Cap ($M) 32
CBL Share Price $0.074
Day High $0.080
Day Low $0.074
Last Close $0.075
CBL Share Price Movement $0.00 ( 1.33% )
Prices as at 16:40, 15 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Control Bionics Limited (CBL) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 1.35¢ 0% 8 Sep 2017 21 Sep 2017 - - -
HFResult 1.83¢ 0% 13 Mar 2017 31 Mar 2017 - - -
Result 2.83¢ 0% 27 Oct 2016 4 Nov 2016 - - -

See all dividends from Control Bionics Limited (CBL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Control Bionics Limited (CBL) price-sensitive announcements

CBL - Completion of Placement
Control Bionics Limited has announced a capital raising initiative, securing firm commitme
Control Bionics Limited (CBL)
25 Jun 2026 | 10:40 AM
CBL - Trading Halt
On 24 June 2026, Control Bionics Limited (CBL) announced a trading halt on its securities
Control Bionics Limited (CBL)
24 Jun 2026 | 10:11 AM
CBL - Pause in Trading
Control Bionics Limited (CBL) announced a temporary pause in trading of its securities on
Control Bionics Limited (CBL)
24 Jun 2026 | 9:49 AM
CBL - Commercial Momentum Presentation
Control Bionics Limited, a global leader in neurotechnology, is working to expand its neur
Control Bionics Limited (CBL)
4 Jun 2026 | 8:27 AM

Control Bionics Limited (CBL) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Control Bionics Limited (CBL)
ORDINARY FULLY PAID
 Health Care $33 Notification of cessation of securities - CBL 7 Jul 2026 12:28PM $0.073 $0.074 risen by 1.37%
Control Bionics Limited (CBL)
ORDINARY FULLY PAID
 Health Care $33 Notification regarding unquoted securities - CBL 6 Jul 2026 5:13PM $0.075 $0.074 fallen by 1.33%
Control Bionics Limited (CBL)
ORDINARY FULLY PAID
 Health Care $33 Notice of General Meeting/Proxy Form 6 Jul 2026 1:25PM $0.073 $0.074 risen by 1.37%
Control Bionics Limited (CBL)
ORDINARY FULLY PAID
 Health Care $33 Change in substantial holding - Phoenix 3 Jul 2026 3:59PM $0.074 $0.074 fallen by 0%
Control Bionics Limited (CBL)
ORDINARY FULLY PAID
 Health Care $33 SPP Cleansing Notice 2 Jul 2026 10:50AM $0.072 $0.074 risen by 2.78%
Control Bionics Limited (CBL)
ORDINARY FULLY PAID
 Health Care $33 Security Purchase Plan Offer Document 2 Jul 2026 10:49AM $0.072 $0.074 risen by 2.78%

CBL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$6.11 -$2.30 -37.50% 0.00 0.00 0.00% 0.0%
2024A -$5.91 -$3.60 -34.10% 0.00 0.00 0.00% 0.0%
2023A -$5.63 -$5.50 -12.80% 0.00 0.00 0.00% 0.0%

CBL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Control Bionics Limited (CBL) $33M -0.3747 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Cochlear Limited (COH) $8,057M 0.0171 -0.1883 0.0862 20.5872 25.3628 23.3510 3.49% 2.81% 3.00%
Fisher & Paykel Healthcare Corporation Limited (FPH) $19,428M 0.1388 0.1334 0.1884 50.0227 44.1361 37.1393 1.31% 1.40% 1.58%
ResMed Inc. (RMD) $16,994M 0.3087 9.7669 0.0812 196.7675 18.2753 16.9030 1.17% 1.23% 1.29%

CBL Directors

Name Position Start Date
Mr Jeremy Steele Chief Executive Officer, Executive Director 19 Jan 2023
Mr Stephen R Rix Non-Executive Chairman, Non-Executive Director 1 Dec 2025
Professor Robert Heard Non-Executive Director 3 May 2023
Mr Damian Lismore Non-Executive Director, Interim Chairman 30 Sep 2020
Professor Nicholas Opie Non-Executive Director, Strategic advisor 14 May 2026

Control Bionics Limited (CBL) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
27 Feb 2026 RIX, Stephen Buy Indirect Shares 587,632 $0.059 $34,828.000
17 Sep 2025 STEELE, Jeremy Issued Indirect Shares 1,142,857 $0.035 $40,000.000
17 Sep 2025 PHILLIPS, Stephanie Issued Direct Shares 30,000 $0.035 $1,050.000

See all changes in directors' interest & trades for Control Bionics Limited (CBL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

CBL Management

Name Position
Shannon Boothroyd Chief Financial Officer
Brett Thomas Crowley Company Secretary
Todd Tyler US Country Manager

CBL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Control Bionics Limited (CBL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
58,495,641 (19.85%) Phoenix Development Fund Limited
56,292,796 (19.10%) Nightingale Partners Pty Limited
20,003,433 (10.04%) Peter Shann Ford

CBL Calendar of Events

Date Event
25 February 2027 Report (Interim)
11 September 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.